COMMUNIQUÉS West-GlobeNewswire

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
06/10/2025
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced [...]
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
06/10/2025
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION [...]
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
06/10/2025
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased [...]
Equillium Announces Leadership and Corporate Updates
06/10/2025
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
06/10/2025
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, [...]
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
06/10/2025
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes [...]
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
06/10/2025
Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, [...]
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
06/10/2025
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a [...]
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
06/10/2025
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on [...]
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
06/10/2025
$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- [...]
Biomea Fusion Announces Proposed Public Offering of Securities
06/10/2025
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering [...]
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
06/10/2025
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking [...]
Counterpart Health Expands Leadership to Accelerate Enterprise Partnerships and Regional Adoption of AI-Powered Platform Counterpart Assistant
06/10/2025
New VP Blaine Lindsey to Drive National Enterprise Growth; Gulf Region President Shannon Jacobs to Scale Operations in High-Need Markets SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“ [...]
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
06/10/2025
Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « [...]
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
06/10/2025
Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/10/2025
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de Pharmakon Advisors et fait un point sur ses activités
06/10/2025
Le nouvel accord de prêt diffère le remboursement de la dette du premier trimestre 2026 au quatrième trimestre 2030, à un taux d’intérêt inférieur au précédent, et offre la possibilité d’obtenir davantage de financement [...]
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
06/10/2025
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business development Company adjusts 2025 financial guidance and provides key [...]
Pharming Group provides update on previously announced G&A expense reduction plan
06/10/2025
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company [...]

Pages